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CASE PRESENTATION (Resident Presentation) 
 A 75-year-old woman with a history of multiple myeloma 
presents to the emergency department (ED) with her daughter 
for chief complaints of fevers and a rash. Much of the history 
was provided by the patient’s daughter, her primary caregiver. 
The patient has had intermittent fevers for three days. The 
fevers occur once or twice a day, last several hours, with 
defervescence between episodes. The highest temperature 
recorded at home was an axillary temperature of 38.6 degrees 
Celsius (C). The patient developed a rash on her left wrist two 
days ago, and yesterday her lip became discolored. The patient 
reports that she has numbness and tingling on both her right 
and left forearms.
The patient was recently hospitalized for pneumonia. 
She was treated with intravenous (IV) antibiotics, after which 
the hospital team changed the patient to an oral antibiotic. 
The daughter believes the name of the oral antibiotic was 
“something with an ox.”
The patient was diagnosed with IgG lambda multiple 
myeloma in 2004 and treated with an autologous stem cell 
transplant in 2005. She has had multiple relapses but at the 
time of presentation was in partial remission. In addition, she 
has a history of therapy-related myelodysplastic syndrome, 
diabetes mellitus, hyperlipidemia, and stage III chronic kidney 
disease. Her home medications are daratumumab, bortezomib, 
lenalidomide, pomalidomide, dexamethasone, acyclovir, 
trimethoprim-sulfamethoxazole, azacitidine, glimepiride, insulin, 
simvastatin, magnesium, calcium carbonate, erythropoietin, and 
vitamin D. She is allergic to penicillins. She has a 30 pack-year 
smoking history but quit more than 25 years ago.
Physical examination revealed an overweight (body mass 
index was 27) white woman sitting up in a stretcher. Her 
temperature was temperature 38.1°C, her blood pressure was 
146/78 millimeters of mercury, her pulse was 86 beats per 
minute, and she was breathing 22 breaths per minute (bpm) 
with an oxygenation saturation of 95% on room air. Her head 
was atraumatic and normocephalic. Her extraocular movements 
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were intact and her pupils were three millimeters in diameter, 
round, equal, and reactive to light. Her oral mucosal membranes 
were moist, with purpura of the lip (Image 1A). Her heart had a 
normal rate and regular rhythm without audible murmurs, rubs 
or gallops. She was mildly tachypneic without clear accessory 
muscle use. Her lungs had diffuse rhonchorous breath sounds 
bilaterally. She had an implanted vascular access port in her 
chest wall and the site was without erythema or induration. 
Her abdomen was soft with normal bowel sounds. She had 
a few small areas of ecchymoses over the abdomen. All four 
extremities were warm and well perfused. Her forearms were 
tender to palpation with some decreased sensation to light 
touch. She had a well circumscribed purpuric lesion on the left 
forearm as shown in Image 1B. Neurologically she was oriented 
to self, place, and time without cranial nerve deficits except 
decreased sensation in the right V3 region in the area of the 
purpuric lip lesion. 
The patient’s initial laboratory results are shown in Table 
1. These were significant for severe leukopenia, anemia, 
and thrombocytopenia consistent with known hematologic 
malignancy. Her chemistry showed mildly impaired renal 
function and elevated glucose. Table 2 shows the results of 
the cultures that were drawn from the patient in the ED. Her 
Images 1A and 1B. Purpura of the lip (A) and forearm lesion (B) 
of a woman with fever and rash.
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Complete blood cell count Coagulation profile
White blood cell count 1.4 K/µL Prothrombin time 16.7 seconds
Hemoglobin 6.3 g/dL Partial thromboplastin time 44.0 seconds
Hematocrit 19.10% International normalized ratio 1.3
Platelets 14 K/µL Urinalysis
Serum chemistries Appearance Cloudy
Sodium 145 mmol/L pH 5.0
Potassium 5.4 mmol/L Ketones Negative
Chloride 109 mmol/L Bilirubin Negative
Bicarbonate 24 mmol/L Protein Negative
Blood urea nitrogen (BUN) 91 mg/dL Nitrite Negative
Creatinine 2.1 mg/dL Red blood cells 3-5 cells per high-powered field
Glucose 303 mg/dL White blood cells 6-10 cells per high-powered field
Calcium 8 mg/dL Venous blood gas
Magnesium 2 mg/dL FiO2 21%
Phosphorous 7 mg/dL Respiratory rate 22 per minute
Total protein 4.7 g/dL pH 7.39
Albumin 2.4 g/dL pCO2 42 mmHg
Aspartate aminotransferase 63 µ/L pO2 26 mmHg
Alanine aminotransferase 78 µ/L HCO3 42 mEq/L
Alkaline phosphatase 206 µ/L HBO2 43.70%
Total bilirubin 0.5 mg/dL Base -0.4 mmol/L
Table 1. Initial laboratory results for a 75-year-old woman presenting with fever and rash.
FiO2, fraction of inspired air; pH, potential of hydrogen; pCO2, partial pressure of carbon dioxide; pO2, partial pressure of oxygen; HCO3, 
bicarbonate; HbO2, oxyhemoglobin; K/µL, kilos per microliter; mg/dL, milligrams per deciliter; g/dL, grams per deciliter; mEq/L, milliequivalents 
per liter; mmol/L, millimoles per liter; mmHg, millimeters mercury.
electrocardiogram (ECG) (Image 2) was unchanged from her 
baseline ECG. Her chest radiograph (CXR) is shown in Image 
3. The patient received antipyretics and was started on broad-
spectrum antibiotics before being admitted to the hospital for 
further workup. An additional test revealed the diagnosis.
CASE DISCUSSION (Attending Discussion) 
When presented with a complex case, I find it helpful to 
succinctly frame the patient presentation: I have a 75-year-
old female with a past medical history of multiple myeloma 
and stem cell transplant, currently on a complex medication 
regimen including immunomodulators and chemotherapy, 
who presents with fever, pancytopenia (likely neutropenia), 
persistent respiratory symptoms despite antibiotics, and a rapidly 
progressive scattered purpuric and necrotic rash. 
My immediate concern after reading this case is neutropenic 
fever, which is defined by a neutropenic patient experiencing a 
single oral temperature of ≥38.3oC or a temperature of ≥38.0oC 
sustained over a one-hour period.1 The description of the 
patient’s fever meets these criteria. Neutropenia is defined as 
an absolute neutrophil count (ANC) <1500 cells per microliter 
(µ/L).2 While the white blood cell (WBC) differential is not 
provided, the total WBC count is 1400 cells/(µ/L), so the patient 
has at least mild neutropenia. This places the patient at risk for 
a broad range of infectious organisms including opportunistic 
bacterial, fungal, and viral infections. Neutropenic patients may 
not develop symptoms of an infection due to a blunted immune 
and inflammatory response, leading to atypical presentations of 
infections. Per the American Society of Clinical Oncology and 
the Infectious Diseases Society of America guidelines, “in the 
absence of an alternative explanation, clinicians should assume 
that fever in a patient with neutropenia from cancer therapy is the 
result of an infection.”3 
Now that the medical emergency has been addressed, we 
can examine the rash. Describing a rash using dermatologic 
terminology helps me narrow the differential diagnosis. This 
patient has several round, umbilicated purpuric papules and 
plaques on her left wrist and right forearm with central necrosis 
that appear in various stages of evolution. The distribution of the 
lesions is asymmetric and may correspond to where peripheral 
IV catheters were placed during her recent hospitalization. 
The patient also has a purpuric and necrotic rash on her right 
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lower lip, with the purpura extending beyond the vermillion 
border. There appear to be pustules or a honey-colored / white 
crust present. Note that there is no mention of any lesions 
involving the oral mucosa. The physical exam describes small 
areas of ecchymoses on the abdomen. This may be part of the 
patient’s purpuric rash or heparin injections during her recent 
hospitalization. Now that I’ve described the rash, I will consider 
the broad categories of causes: bacterial, fungal, and viral 
infections, as well as non-infectious etiologies.
Bacterial infections are the most frequent cause of 
infection in patients with neutropenic fever.3 More than half 
are due to gram-positive organisms such as Staphylococcus 
or Streptococcus species (especially Staphylococcus 
Epidermiditis).3 She was recently hospitalized, raising 
suspicion for hospital-acquired and drug resistant organisms. 
I suspect the patient was discharged on levofloxacin 
(“something with an ox”), an antibiotic appropriate for 
treating community-acquired pneumonia and the empiric 
treatment of neutropenic fever.1,3 Purpura fulminans can 
occur in immunosuppressed patients and is described as 
petechiae that rapidly progress to purpura and necrotic lesions 
within hours. Neisseria meningitidis or varicella are the most 
common causes, but pneumococcus, Staphylococcus, and 
streptococci are also implicated. But patients with purpura 
fulminans are often critically ill, suffering from septic shock 
and disseminated intravascular coagulation, which does not fit 
with this patient’s presentation.
Our patient’s blood cultures did not grow any bacterial 
pathogens and her symptoms progressed despite antibiotics, 
so we have to consider fungal infections, especially since 
they can cause persistent or recurrent fevers. Our patient has 
a number of risk factors for fungal disease (a central venous 
catheter, hematologic malignancy, stem cell transplant, 
diabetes, and glucocorticoid treatment) and she is not on 
fluconazole prophylaxis.
Disseminated candidiasis can be seen in neutropenic 
patients after a disruption of the gastrointestinal mucosa 
(common in chemotherapy) or from central venous 
catheters. It presents as a scattered, diffuse, maculopapular 
or pustular rash; rarely the rash may be purpuric.  
Endophthalmitis may be seen, but lung involvement is rare, 
making this an atypical case and therefore disseminated 
candidiasis is unlikely in this patient.
Patients with disseminated aspergillus infections typically 
present with cough, fever, and hemoptysis. CXR may show 
single or multiple nodules with or without cavitation, but 
neutropenic patients may present with segmental consolidation 
as seen in our patient. Hematologic dissemination can rarely lead 
to skin lesions that typically manifest as subcutaneous nodules 
or pustules that evolve into purpuric and necrotic lesions with an 
ecthyma gangrenosum-like appearance. 
Patients with diabetes and immunosupression are at risk for 
mucormycosis. The most common form is rhino-orbital-cerebral 
mucormycosis, which presents as erythema and swelling in the 
skin overlying the sinuses or orbits. The patient’s skin lesion is 
located on her lower lip, and she does not appear to have any 
sinus involvement making mucormyosis less likely. Cutaneous 
mucormycosis is rarer and is associated with trauma or wounds, 
appearing as a single painful ecythma-like lesion. 
Endemic fungi such as Histoplasma capsulatum, 
Blastomyces dermatiditis, and Coccidioides spp are also 
possibilities. However, blastomyces and coccidioides are not 
endemic to the Mid-Atlantic, and Histoplasma is uncommon.4 
The rash of disseminated histoplasmosis is described as diffusely 
scattered erythematous papules and nodules which may be 
umbilicated or crusted, inconsistent with this patient’s rash.
Reactivation of herpes simplex-1 (HSV-1), herpes 
simplex-2 (HSV-2), and varicella zoster virus are also 
important infections to consider in neutropenic patients or 
those taking medications such as bortezomib.5 However, the 
patient’s rash is not typical for herpes or zoster and the patient 
is taking acyclovir for prophylaxis.
Stevens-Johnson syndrome / toxic epidural necrolysis 
(SJS/TEN) is a non-infectious cause of rash that presents 
with fever and muco-cutaneous lesions. The rash typically 
begins on the face and trunk as coalescing macules with 
purpuric centers before spreading to the extremities in a 
symmetric distribution.6 Over hours to days bullae form, 
and the skin may begin to slough off. The oral mucosa 
and vermillion border are almost always involved, with 
hemorrhagic erosions covered by crusting or a grayish-white 
membrane. Patients with active malignancy are at increased 
risk and our patient is on multiple medications that have 
been implicated in SJS / TEN: lenalidomide, pomalidomide, 
and trimethoprim-sulfamethoxazole.7 However, the risk of 
SJS / TEN is thought to be limited to the first eight weeks 
of taking a medication. Further, our patient’s rash is not 
symmetric, making SJS / TEN less likely.
Thrombotic thrombocytopenic purpura (TTP) is worth 
considering. The classic pentad of  TTP includes fever, 
thrombocytopenic purpura, microangiopathic hemolytic anemia, 
renal dysfunction, and neurologic symptoms. Our patient has 
fever, thrombocytopenic purpura, anemia, and renal dysfunction. 
The PLASMIC scoring system can be used to identify patients 
with severe ADAMS13 deficiency who would benefit from 
plasma exchange.8 While the patient has thrombocytopenia, 
Source Result
Blood #1 No growth
Blood #2 No growth
Urine No growth
Sputum No growth
Table 2. Culture results of woman with fever and rash.
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Image 2. Electrocardiogram of febrile cancer patient showing sinus rhythm and known bifascicular block.
her active cancer and her stem-cell transplant history, her low 
bilirubin, and high creatinine make it unlikely that she has TTP.
Multiple myeloma itself can very rarely present with fever 
and skin lesions. The skins lesions can occur due to infiltration 
of plasma cells into the skin (plasmacytomas), deposition of 
protein (amyloid, cryoglobulins), or secondary to cytopenias 
(i.e. thrombocytopenia). Plasmacytomas are typically not 
purpuric or necrotic, and the lesions do not arise over the course 
of hours to days. Amyloidosis secondary to multiple myeloma 
can present with purpuric lesions on the face and extremities, 
classically on the eyelids and periorbital area. The lesions 
often have a linear or geometric shape occurring due to minor 
trauma (“pinch purpura”). The patient’s lesions do not have this 
classic appearance or distribution. Further, the patient is also 
lacking other features of amyloidosis such as proteinuria and/or 
restrictive cardiomyopathy.
Cutaneous vasculitis can present with petechiae and purpura. 
If the vasculitis results in vascular occlusion the lesions can 
become necrotic and ulcerate. There is a long list of causes 
for cutaneous vasculitis including drug reactions, infections, 
malignancy, and rheumatologic causes. One potential cause 
of cutaneous vasculitis worth considering in this patient is 
cryoglobulinemia due to multiple myeloma. In cryoglobulinemia, 
cold causes high circulating levels of immunoglobulins to 
precipitate resulting in obstruction of distal small blood 
vessels and rarely an inflammatory vasculitis. Lesions have a 
predilection for the extremities, particularly acral areas with 
Raynaud phenomenon and digital ischemia sometimes occurring. 
Cryoglobulinemia is unlikely in this case given the distribution 
of the lesions, lack of reported cold intolerance, and lack of other 
organ involvement (i.e., glomerulonephritis). 
One more non-infectious entity to consider are the 
neutrophilic dermatoses (ND) such as Sweet’s syndrome or 
pyoderma gangrenosum. There is an association between ND 
and hematologic malignancies, active chemotherapy, and 
being over the age of 65.9 In these conditions, inflammatory 
papules or pustules progress to ulcerations with a necrotic base 
and a bluish or violaceous margin. As in our case, the rash can 
present where a patient has had a recent procedure or injury. 
The diagnosis is made by meeting two minor criteria (recent 
respiratory illness, fevers, hematologic malignancy, recent 
vaccination, response to steroids, and elevated erythrocyte 
sedimentation rate) and two major criteria (classic rash and 
a biopsy showing neutrophilic infiltrate).10 While rare, this 
patient meets one of the major criteria and many of the minor 
criteria for ND. The one missing criterion is a diagnostic test. 
If I were the first physician to care for this patient when 
they presented to the ED, my chief concern would be presumed 
sepsis in the neutropenic and febrile patient. Once the patient’s 
medical emergency is managed, I would consider other causes 
of their fever. In this case, I believe they have a ND, and a skin 
biopsy would be the diagnostic test of choice. 
CASE OUTCOME (Resident Presentation) 
The diagnostic test ordered was a punch biopsy of 
the skin. The pathology report demonstrated sheets of 
neutrophils in the upper dermis with less involvement in the 
deeper dermis, consistent with acute neutrophilic dermatosis 
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Fifteen to twenty percent of Sweet’s syndrome cases are 
associated with a malignancy, most commonly hematologic 
cancer.13 Acute myelogenous leukemia is the most common 
cancer, followed by myeloproliferative diseases such as that of 
our patient. Sweet’s syndrome can occur before, during, or after a 
malignancy, though the development of Sweet’s syndrome while 
in remission may signal disease recurrence.1 
Drug-induced Sweet’s syndrome has been associated with 
immunomodulating drugs (granulocyte macrophage colony 
stimulating factor, filgrastim and lenograstim, ipilimumab, 
bortezomib, and azathioprine,) and chemotherapy agents.14 
Surprisingly, azathioprine has been identified as both a 
possible cause and treatment for Sweet’s syndrome. Antibiotics 
(trimethoprim-sulfamethoxazole and minocycline), and anti-
hypertensives (hydralazine) have been shown to induce Sweet’s 
syndrome. Our patient was taking three of these medications.
The pathophysiology of Sweet’s syndrome is uncertain. 
Marzano et al. (2014) performed protein arrays of patients with 
both pyoderma gangrenosum and Sweet syndrome, noting 
an increase in pro-inflammatory cytokines interleukin-1β, 
interleukin-6, and interleukin-8, and tumor necrosis factor-α.15 
Increased levels of granulocyte-colony stimulating factor have 
also been associated with both acute myelogenous leukemia and 
Sweet’s syndrome.16 Recent research has found mutations in 
the isocitrate dehydrogenase protein, which activates oncogenes 
and inactivates tumor suppressor genes, in individuals with 
myelodysplastic syndrome and Sweet’s syndrome.17
The major criteria for classical or malignancy-associated 
Sweet’s syndrome include 1) an abrupt onset of painful 
erythematous plaques or nodules, and 2) histology of skin lesions 
showing a neutrophilic infiltrate in the absence of infection or 
vasculitis.18 Minor criteria include 1) fever greater than 38oC, 
2) an association with malignancy, inflammatory or infectious 
disease, or vaccination, and 3) elevation of inflammatory markers 
such as erythrocyte sedimentation rate (ESR), C-reactive protein 
(CRP), white cell count or percentage of neutrophils. Patients 
with underlying hematologic malignancies may present with 
neutropenia rather than neutrophilia. Both major criteria and 
two out of four minor criteria are required for diagnosis. The 
diagnostic criteria of drug-induced Sweet’s syndrome also 
requires a temporal relationship between the offending agent 
and the course of symptoms.19 In the case presented, our patient 
met diagnostic clinical criteria and had features that were 
consistent with all three forms of Sweet’s syndrome.
The clinical course of Sweet’s syndrome is highly 
variable, with fever being the most common presenting 
symptom. Intermittent fevers may occur for days to weeks 
prior to development of cutaneous findings. Symmetric 
lesions on the upper extremities or head and neck are the 
most common cutaneous features. Although the cutaneous 
eruptions may begin as papules or nodules, they can enlarge 
and form into irregular plaques. It is not unusual for these 
lesions to occur in areas of cutaneous trauma, such as 
Image 3. Chest radiograph of febrile cancer patient with left-sided 
chemotherapy port in place.
(Sweet’s syndrome). The leukemia service recommended 
starting the patient on one milligram per kilogram (mg/kg) 
of methylprednisone and the patient quickly defervesced. 
Steroids were tapered slowly over the following month with 
the lesions on the lip and upper extremities treated with local 
wound care. The patient was discharged shortly thereafter. 
RESIDENT DISCUSSION
Sweet’s syndrome was first described by Robert Sweet 
in 1964 as a constellation of symptoms including fever, 
leukocytosis, and tender erythematous papules and plaques, and 
a mature neutrophilic infiltrate.11 Sweet’s syndrome has since 
been linked to hematologic malignancies immune disorders, 
such as pyoderma gangrenosum, leading researchers to 
conclude that these diseases might be grouped as “a continuous 
pathologic spectrum” known as neutrophilic dermatoses ND.12
ND are characterized by a cutaneous neutrophilic 
infiltrate without evidence of infection. Patients with ND 
may have extracutaneous neutrophilic infiltrates, which will 
present as systemic diseases such as inflammatory bowel 
disease and rheumatoid arthritis. Traditionally, ND have 
transitional and overlap forms, or manifestations that either 
progress from one ND to another or represent an intersection 
of more than one ND.12  
Sweet’s syndrome can be broken into classical, 
malignancy-associated, and drug-induced. Classical Sweet 
represents approximately half of all cases, typically affecting 
women 30-50 years old. The disease has no clear geographical 
or ethnic predisposition. The classical form most commonly 
involves the upper extremities and it may be preceded by a 
gastrointestinal or respiratory infection. 
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venipuncture sites. Patients often have hyperalgesia in the 
areas of skin findings, which resolves over the course of days 
to weeks with treatment. 
Unfortunately, even characteristic clinical and historical 
disease features are inadequate to rule out other possible 
etiologies of fever, particularly in cancer patients who are 
immunocompromised. Malignancy-associated Sweet’s 
syndrome presents a unique diagnostic challenge as it is 
most commonly associated with hematologic cancers. 
Although the cyclic or intermittent fevers and dermatologic 
findings may be a diagnostic clue, a high level of suspicion 
must be maintained for other sources of fever. Thus, these 
patients should undergo a standard fever workup, including 
urinalysis, blood cultures, and CXR. In addition to complete 
blood count and chemistries of renal and liver function, 
inflammatory markers such as CRP and ESR may help to 
differentiate between sources of fever. Empiric antibiotic 
treatment while awaiting cultures is important in patients 
who present with febrile neutropenia of uncertain etiology. 
It is important to consider early involvement of dermatology 
for a skin biopsy in patients who have intermittent fevers and 
characteristic dermatologic findings. 
First-line treatment of Sweet’s syndrome is 0.5-
1.0 mg/kg continued for four to six weeks of systemic 
glucocorticoids.20 Symptoms generally improve or resolve 
within the first one to two weeks. Local corticosteroids 
may be used in cases of few lesions with no systemic 
symptoms. Potassium iodide has some efficacy and can be 
given as a 300 mg tablet three times daily or a solution dosed 
at 1000 mg/day. In the case of drug-induced Sweet’s syndrome, 
the offending agent should also be discontinued. There are 
literature reports of malignancy-associated Sweet’s syndrome 
resolving with treatment of the cancer.19,20 Similarly, an unknown 
malignancy must be considered when a diagnosis of Sweet’s 
syndrome is made.20
Since the episode, the patient has not had a recurrence 
of Sweet’s syndrome, although she has had progression of 
her multiple myeloma and myelodysplastic syndrome with 
poor prognosis. 
FINAL DIAGNOSIS
Sweet syndrome secondary to multiple myeloma and 
myelodysplastic syndrome.
KEY TEACHING POINTS 
•	 Consider non-infectious causes of fever in 
immunocompromised patients, particularly patients with 
known malignancies. 
•	 Sweet’s syndrome should be considered in 
patients with a rash and fever, especially when there 
is associated malignancy, inflammatory or infectious 
disease, or vaccination.
•	 Chemotherapy patients are often on 
complicated regimens of medications with numerous 
and clinically relevant side effects; maintain a high 
degree of suspicion for the role of immunomodulators in 
disease processes.
•	 If an apparently healthy patient without 
recent medication changes or viral illness is 
diagnosed with Sweet’s syndrome, that patient should 
undergo a workup for underlying malignancy.
•	 Assume that neutropenic patients 
presenting with fever are septic and resuscitate them 
aggressively, even though they may appear clinically 
to be well.
Documented patient informed consent and/or Institutional Review 
Board approval has been obtained and filed for publication of this 
case report.
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